Safety and Pharmacokinetics Study of MT-3921 in Spinal Cord Injury
Condition: Spinal Cord Injury Interventions: Biological: MT-3921 Low dose; Biological: MT-3921 High dose Sponsor: Mitsubishi Tanabe Pharma Development America, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials